Regimen for the Treatment of Cachexia in Subjects With NSCLC
Status:
Completed
Trial end date:
2008-09-01
Target enrollment:
Participant gender:
Summary
Cachexia is a presentation of a chronic manifestation of acute metabolic stress, a
hypercatabolic nutritional state in which the normal fat and protein sparing mechanisms are
not functioning and increased nutrition is not utilized.
To switch the nutritional system from a hypercatabolic to a normal nutritional state, therapy
must block multi-factorial stress signaling a threshold of activation. Consistent with the
synergistic hypothesis, propranolol and etodolac have been evaluated in subjects with
advanced cancer demonstrating cachexia. This trial will evaluate the safety and efficacy of
VT-122 in subjects with NSCLC who have hypercatabolic cachexia.